|
|
Authors |
Khera
AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri
K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler
ER, Rothblat GH, Rader DJ.
|
Title |
Cholesterol
efflux capacity, high-density lipoprotein function, and atherosclerosis
|
Full
source |
N Engl J Med 2011;364:127-35 |
|
|
Per scorrere le diapositive
|
|
Abstract
|
BACKGROUND: High-density lipoprotein (HDL) may provide cardiovascular
protection by promoting reverse cholesterol transport from macrophages.
We hypothesized that the capacity of HDL to accept cholesterol
from macrophages would serve as a predictor of atherosclerotic
burden.
METHODS: We measured cholesterol efflux capacity in 203 healthy
volunteers who underwent assessment of carotid artery intima-media
thickness, 442 patients with angiographically confirmed coronary
artery disease, and 351 patients without such angiographically
confirmed disease. We quantified efflux capacity by using a validated
ex vivo system that involved incubation of macrophages with apolipoprotein
B-depleted serum from the study participants.
RESULTS: The levels of HDL cholesterol and apolipoprotein A-I
were significant determinants of cholesterol efflux capacity but
accounted for less than 40% of the observed variation. An inverse
relationship was noted between efflux capacity and carotid intima-media
thickness both before and after adjustment for the HDL cholesterol
level. Furthermore, efflux capacity was a strong inverse predictor
of coronary disease status (adjusted odds ratio for coronary disease
per 1-SD increase in efflux capacity, 0.70; 95% confidence interval
[CI], 0.59 to 0.83; P<0.001). This relationship was attenuated,
but remained significant, after additional adjustment for the
HDL cholesterol level (odds ratio per 1-SD increase, 0.75; 95%
CI, 0.63 to 0.90; P=0.002) or apolipoprotein A-I level (odds ratio
per 1-SD increase, 0.74; 95% CI, 0.61 to 0.89; P=0.002). Additional
studies showed enhanced efflux capacity in patients with the metabolic
syndrome and low HDL cholesterol levels who were treated with
pioglitazone, but not in patients with hypercholesterolemia who
were treated with statins.
CONCLUSIONS: Cholesterol efflux capacity from macrophages, a metric
of HDL function, has a strong inverse association with both carotid
intima-media thickness and the likelihood of angiographic coronary
artery disease, independently of the HDL cholesterol level. (Funded
by the National Heart, Lung, and Blood Institute and others.).
|
|